STRATA Skin Sciences Seeks 520,000 Share Boost to Equity Plan

TL;DR

**SSKN is asking shareholders to greenlight a massive 520,000 share increase to its equity plan, signaling potential dilution and a need to scrutinize executive compensation.**

AI Summary

STRATA Skin Sciences, Inc. (SSKN) is holding its 2025 Annual Meeting of Stockholders on December 10, 2025, to address several key proposals. Stockholders will vote on the election of five director nominees and the ratification of CBIZ, CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. A significant proposal is the approval of an amendment to the Amended and Restated 2016 Omnibus Incentive Plan, seeking to increase the number of shares of common stock reserved for issuance by 520,000 shares. As of March 31, 2025, there were 4,171,161 shares of common stock outstanding, with 5,268,708 shares entitled to vote on the October 13, 2025 record date. Major beneficial owners include Accelmed Partners LP with 34.55% (1,441,835 shares), 22NW Fund, LP with 15.32% (536,995 shares), and Nantahala Capital Management, LLC with 9.68% (312,813 shares). Dr. Dolev Rafaeli, President and CEO, beneficially owns 3.95% (143,156 shares). The proposed increase in the equity incentive plan could lead to further dilution for existing shareholders.

Why It Matters

This DEF 14A filing is crucial for SSKN investors as it outlines proposals that could significantly impact shareholder value and corporate governance. The request to increase the 2016 Omnibus Incentive Plan by 520,000 shares, representing a substantial portion of the 4,171,161 shares outstanding as of March 31, 2025, could lead to notable dilution for existing shareholders. This move might be perceived as a way to attract and retain key talent, but it also signals potential future stock-based compensation expenses. Competitively, a robust incentive plan can help SSKN attract top executives and employees in the medical aesthetics and dermatology device market, but excessive dilution could make the stock less attractive compared to peers with more conservative compensation structures.

Risk Assessment

Risk Level: medium — The proposal to increase the 2016 Omnibus Incentive Plan by 520,000 shares, when only 4,171,161 shares were outstanding as of March 31, 2025, represents a potential dilution of over 12% of the current outstanding shares. This significant increase in potential share issuance could negatively impact existing shareholder value and warrants careful consideration.

Analyst Insight

Investors should carefully review Proposal No. 2 regarding the 520,000 share increase to the equity incentive plan. Consider the potential dilution and its impact on your ownership percentage and the stock's valuation. Vote 'Against' if you believe the proposed increase is excessive or not adequately justified by the company's performance or strategic needs.

Key Numbers

• 520,000 shares — Increase in shares reserved for 2016 Equity Incentive Plan (Proposed increase in shares for equity compensation, potentially dilutive.)
• December 10, 2025 — Date of Annual Meeting of Stockholders (Key date for voting on proposals.)
• October 13, 2025 — Record date for Annual Meeting (Date by which stockholders must own shares to vote.)
• 5,268,708 shares — Common stock outstanding and entitled to vote on record date (Total shares eligible to vote at the Annual Meeting.)
• 4,171,161 shares — Common stock outstanding as of March 31, 2025 (Base for calculating beneficial ownership percentages.)
• 34.55% — Beneficial ownership of Accelmed Partners LP (Largest beneficial owner, indicating significant influence.)
• 15.32% — Beneficial ownership of 22NW Fund, LP (Second largest beneficial owner.)
• 9.68% — Beneficial ownership of Nantahala Capital Management, LLC (Third largest beneficial owner.)
• 3.95% — Beneficial ownership of Dr. Dolev Rafaeli (CEO's stake in the company.)
• 5 — Number of director nominees (Number of individuals proposed for election to the Board of Directors.)

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — Registrant
• Dr. Dolev Rafaeli (person) — President and Chief Executive Officer
• CBIZ, CPAs P.C. (company) — Independent registered public accounting firm
• Accelmed Partners LP (company) — Beneficial owner with 34.55% stake
• Uri Geiger (person) — Managing Partner at Accelmed, beneficial owner
• 22NW Fund, LP (company) — Beneficial owner with 15.32% stake
• Nantahala Capital Management, LLC (company) — Beneficial owner with 9.68% stake
• Equiniti Trust Company, LLC (company) — Transfer agent
• Securities and Exchange Commission (regulator) — Regulatory body
• Board of Directors (person) — Governing body of STRATA Skin Sciences, Inc.

FAQ

Industry Context

STRATA Skin Sciences operates in the medical aesthetics industry, focusing on devices for dermatological and aesthetic procedures. This sector is characterized by innovation in technology, increasing consumer demand for non-invasive treatments, and a competitive landscape with both established players and emerging companies. Regulatory approvals and reimbursement policies can significantly impact market access and adoption of new technologies.

Regulatory Implications

The company's operations are subject to regulatory oversight by bodies like the FDA for its medical devices. Compliance with manufacturing standards, marketing regulations, and data privacy laws is critical. Changes in healthcare policy or reimbursement rates could also affect the company's financial performance and market penetration.

What Investors Should Do

1. Review the proposed amendment to the 2016 Omnibus Incentive Plan.
2. Evaluate the director nominees.
3. Consider the ratification of the independent auditor.

Key Dates

• 2025-12-10: 2025 Annual Meeting of Stockholders — Key date for voting on director elections, auditor ratification, and equity incentive plan amendments.
• 2025-10-13: Record Date for Annual Meeting — Stockholders must own shares by this date to be eligible to vote at the Annual Meeting.
• 2025-03-31: Outstanding Shares as of March 31, 2025 — Used as the base for calculating beneficial ownership percentages.
• 2024-12-31: Fiscal Year End — The independent auditor will be engaged for this fiscal year.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual meeting of stockholders, including proposals to be voted on. (This document contains the information being analyzed, including proposals for director elections, auditor ratification, and equity incentive plan changes.)

Amended and Restated 2016 Omnibus Incentive Plan

A company plan that allows for the granting of stock options, restricted stock, and other equity-based awards to employees and directors. (A proposal seeks to increase the number of shares reserved under this plan, which could impact shareholder dilution.)

Beneficial Ownership

The actual right to use or dispose of a security, even if the security is registered in someone else's name. (The filing details who owns significant portions of STRATA Skin Sciences' stock, including major institutional investors and management.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends or vote at a shareholder meeting. (Determines eligibility to vote at the 2025 Annual Meeting of Stockholders.)

Street Name

When a security is held in an account at a brokerage firm or bank on behalf of the investor, rather than being registered directly in the investor's name. (Explains how beneficial owners, who do not hold shares directly, can still direct their vote.)

Year-Over-Year Comparison

This DEF 14A filing focuses on the upcoming 2025 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and an increase in the equity incentive plan shares. Unlike a typical annual report (10-K), it does not provide a comprehensive overview of the previous fiscal year's financial performance, such as revenue, net income, or margin changes. The key financial data points available relate to share counts and ownership percentages as of specific dates in 2025 and 2024, rather than year-over-year operational comparisons.

Filing Documents

• ny20055407x2_def14a.htm (DEF 14A) — 890KB
• ny20055407x2_pc01.jpg (GRAPHIC) — 589KB
• ny20055407x2_pc02.jpg (GRAPHIC) — 557KB
• ny20055407x2_pvpchart01.jpg (GRAPHIC) — 123KB
• ny20055407x2_pvpchart02.jpg (GRAPHIC) — 122KB
• 0001140361-25-039879.txt ( ) — 5885KB
• sskn-20251210.xsd (EX-101.SCH) — 3KB
• sskn-20251210_def.xml (EX-101.DEF) — 3KB
• sskn-20251210_lab.xml (EX-101.LAB) — 2KB
• sskn-20251210_pre.xml (EX-101.PRE) — 5KB
• ny20055407x2_def14a_htm.xml (XML) — 575KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 6 CORPORATE GOVERNANCE 7 REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS 11 SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE 12

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 13 DIRECTOR COMPENSATION 22 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 23 PROPOSAL NO. 1 24 PROPOSAL NO. 2 26 PROPOSAL NO. 3 32 HOUSEHOLDING OF PROXY MATERIALS 34 OTHER MATTERS 35 i TABLE OF CONTENTS STRATA SKIN SCIENCES, INC. 5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044 PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING Why am I receiving these materials? You received this Proxy Statement and the enclosed proxy card because the Board of Directors of STRATA Skin Sciences, Inc. ("we", "us", "our", or "the Company") is soliciting your proxy to vote at our 2025 Annual Meeting of Stockholders (the "Annual Meeting"). You are invited to attend the Annual Meeting, and we request that you vote on the proposals described in this Proxy Statement. You do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or you may grant a proxy to vote your shares by means of the telephone or on the Internet. We intend to mail this Proxy Statement and the accompanying proxy card together with our 2024 Annual Report to Stockholders on or about October 30, 2025 to all stockholders of record on October 13, 2025 (the "record date") entitled to vote at the Annual Meeting. Each share of common stock outstanding on the record date will be entitled to one vote. Who can vote at the Annual Meeting? Only stockholders of record at the close of business on the record date will be entitled to vote at the Annual Meeting. On this record date, there were 5,268,708 shares of common stock outstanding and entitled to vote. Stockholder of Record: Shares Registered in Your Name If, on the record date, your shares were registered directly in your name with our transfer agent, Equiniti Trust Company, LLC, then you are a stockholder of record. As a stockholder of record, you may vote i

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table reflects, as of March 31, 2025, the beneficial common stock ownership of: (a) each of our directors, (b) each executive officer, (c) each person known by us to be a beneficial holder of five percent (5%) or more of our common stock, and (d) all of our executive officers and directors as a group. Unless otherwise provided in the accompanying footnotes, the information used in the table below was obtained from the referenced beneficial owner. Name and Address of Beneficial Owner (1) Number of Shares Beneficially Owned Percentage of Shares Beneficially Owned (1) Uri Geiger (3) 1,441,835 34.55% Dolev Rafaeli (6) 143,156 3.95% Irit Yaniv (7) 2,000 * Samuel Rubinstein (8) 19,860 * Shmuel Gov (2) 99,125 * John Gillings 0 * All directors and officers as a group (seven persons) 40.92% Accelmed Partners LP (3) 1,211,262 34.55% Nantahala Capital Management, LLC (4) 312,813 9.68% 22NW Fund, LP (5) 536,995 15.32% * Less than 1%. (1) Beneficial ownership is determined in accordance with the rules of the Commission. Shares of common stock subject to delivery, or subject to options or warrants currently exercisable, or exercisable within 60 days of March 31, 2025 are deemed outstanding for computing the percentage ownership of the stockholder holding the options or warrants, but are not deemed outstanding for computing the percentage ownership of any other stockholder. Unless otherwise indicated in the footnotes to this table, we believe stockholders named in the table have sole voting and sole investment power with respect to the shares set forth opposite such stockholder's name. Unless otherwise indicated, the listed officers, directors and stockholders can be reached at our principal offices. Percentage of ownership is based on 4,171,161 shares of common stock outstanding as of March 31, 2025. (2) Holdings include exe

View Full Filing

View this DEF 14A filing on SEC EDGAR